论文部分内容阅读
新辅助同期化放疗,是手术前同期联合化放疗的治疗方法。利用化疗与放疗的协同增敏效应,其对远期生存的影响优于化放疗的序贯联合。化放疗的术前同期联合,目的主要在于通过临床降期来提高病灶切除率,防止远处转移的出现。本文在复习相关文献的基础上,对近年来食管癌新辅助同期化放疗临床研究进展,化放疗具体方案实施,以及同期化放疗后再实施手术治疗的意义,进行了系统的综述。
Neo-assisted concurrent radiotherapy is the same period before surgery combined with radiotherapy treatment. The use of chemotherapy and radiotherapy synergistic sensitization effect, its long-term survival is better than the sequential combination of radiotherapy. Preoperative combination of radiotherapy and chemotherapy, the main purpose is to improve the clinical resection rate of resection, to prevent the emergence of distant metastases. Based on the review of relevant literature, this review summarizes the recent progress in the clinical research of esophageal neoadjuvant chemoradiotherapy, the implementation of specific radiotherapy and chemotherapy programs, and the significance of surgical treatment after concurrent radiotherapy.